My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

206.60 -4.72 (-2.23%)

Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

97 98 Next >

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation ↗

April 09, 2026

The calendar says it’s spring, but investors can’t be blamed for feeling like it’s Groundhog Day: The economic issues impacting portfolios continue to persist this year. Just after a ceasefire between...

Via MarketBeat

Topics Economy

3 Companies Aggressively Raising Dividends While Others Play Defense ↗

April 09, 2026

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

Via MarketBeat

Topics Artificial Intelligence Economy

This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM ↗

April 09, 2026

The Invesco BulletShares 2028 Corporate Bond ETF holds a diversified portfolio of investment-grade U.S. corporate bonds maturing in 2028.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

This Fund's Ladder Strategy Expanded With a $4 Million Buy in One 2027 Bond ETF ↗

April 09, 2026

This ETF targets investment-grade U.S. corporate bonds maturing in 2027, offering defined duration and a predictable income stream.

Via The Motley Fool

Topics Bonds ETFs

Red Spruce Adds $3.35 Million to a 2029 Bond ETF With 4.5% Yield. Here's What Investors Should Know ↗

April 09, 2026

The Invesco BulletShares 2029 Corporate Bond ETF targets investment-grade U.S. bonds maturing in 2029 with a defined maturity structure.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

1 Healthcare Stock on Our Watchlist and 2 We Avoid

April 09, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗

April 08, 2026

These stocks offer high yields and trade at incredibly low earnings multiples.

Via The Motley Fool

Topics Economy

This Pharma Dividend Has Been Raised Every Single Year for Over a Decade ↗

April 07, 2026

Spun off from a Dividend King in 2013, this pharmaceutical stock is a rising star among dividend growth stocks.

Via The Motley Fool

Topics Intellectual Property

Should You Buy AbbVie Stock Before April 29? ↗

April 07, 2026

The healthcare giant reports earnings in three weeks.

Via The Motley Fool

Topics Intellectual Property

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗

April 02, 2026

Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.

Via The Motley Fool

Topics Economy Retirement Stocks

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends ↗

March 27, 2026

The stock has averaged annual gains of 16.2% over the past decade, and it sports a generous dividend yield, too.

Via The Motley Fool

Topics Intellectual Property

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

Topics Cannabis Initial Public Offering Intellectual Property

The Fed Is Worried About Trump-Fueled Inflation. Are Your Stocks Safe? ↗

March 25, 2026

Investors should be prepared in case inflation remains higher than expected.

Via The Motley Fool

Topics Economy Government World Trade

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

This pair busts the myth of the sector being a desert for income investors.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗

March 23, 2026

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Via The Motley Fool

Topics ETFs Intellectual Property

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Best Healthcare Stocks to Buy After the Market Pullback ↗

March 20, 2026

They have the means to recover from recent setbacks.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

97 98 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.